[Federal Register Volume 77, Number 30 (Tuesday, February 14, 2012)]
[Notices]
[Pages 8270-8271]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-3440]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: Recombinant DNA Advisory Committee.
Date: March 7-8, 2012.
Time: March 7, 2012, 3:30 p.m. to 5:30 p.m.
Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will
review and discuss selected human gene transfer protocols and
related data management activities. Please check the meeting agenda
at
[[Page 8271]]
OBA Meetings Page (available at the following URL: http://oba.od.nih.gov/rdna_rac/rac_meetings.html) for more information.
Place: National Institutes of Health, Building 31C, 9000
Rockville Pike, Conference Room 6 & 8, Bethesda, MD 20892.
Time: March 8, 2012, 8:30 a.m. to 3:00 p.m.
Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will
review and discuss selected human gene transfer protocols and
related data management activities. Please check the meeting agenda
at OBA Meetings Page (available at the following URL: http://oba.od.nih.gov/rdna_rac/rac_meetings.html) for more information.
Place: National Institutes of Health, Building 31C, 9000
Rockville Pike, Conference Room 6 & 8, Bethesda, MD 20892.
Contact Person: Chezelle George, Office of Biotechnology
Activities, Office of Science Policy/OD, National Institutes of
Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892, 301-496-
9838, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
OBA will be piloting a new system to offer those members of the
public viewing the meeting via webcast (see link on OBA Meetings
Page) the opportunity to submit comments to be read during the
scheduled public comment periods. Individuals wishing to submit
comments should use the comment form, which will accommodate
comments up to 1500 characters, and will be available on the OBA
Meetings Page during the meeting. Please submit your comment prior
to the start of the public comment period. Please limit your comment
to a statement that can be read in one to two minutes. Please
include your name and affiliation with your comment.
OBA will read comments into the record during the public comment
periods that are specified on the agenda. Please note, while every
effort is made to keep the meeting discussions to the times stated
on the agenda, it is not unusual for the meeting to run ahead or
behind schedule due to changes in the time needed to review a
protocol. It is advisable to monitor the webcast to determine when
public comments will be read. Comments submitted electronically will
follow any comments by individuals attending the meeting in person.
Comments will be read in the order received and your name and
affiliation will be read with the comment. Please note OBA may not
be able to read every comment received in the time allotted for
public comment. Comments not read will become part of the public
record.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: http://oba.od.nih.gov/rdna/rdna.html, where an agenda and any
additional information for the meeting will be posted when
available.
OMB's ``Mandatory Information Requirements for Federal
Assistance Program Announcements'' (45 FR 39592, June 11, 1980)
requires a statement concerning the official government programs
contained in the Catalog of Federal Domestic Assistance. Normally
NIH lists in its announcements the number and title of affected
individual programs for the guidance of the public. Because the
guidance in this notice covers virtually every NIH and Federal
research program in which DNA recombinant molecule techniques could
be used, it has been determined not to be cost effective or in the
public interest to attempt to list these programs. Such a list would
likely require several additional pages. In addition, NIH could not
be certain that every Federal program would be included as many
Federal agencies, as well as private organizations, both national
and international, have elected to follow the NIH Guidelines. In
lieu of the individual program listing, NIH invites readers to
direct questions to the information address above about whether
individual programs listed in the Catalog of Federal Domestic
Assistance are affected.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: February 7, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-3440 Filed 2-13-12; 8:45 am]
BILLING CODE 4140-01-P